Mirnax Biosens

Mirnax Biosens, SL is a biotechnology company owned by Canaan Research & Investment, SL, aimed at developing novel disruptive technologies based on liquid biopsy for the fields of diagnostics and clinical prognosis in the health sector. MIRNAX is developing a universal and innovative validation platform for genetic biomarkers of different biological natures (DNA, RNA, miRNA, etc.), providing the market with microqPCR-based technology capable of rapidly generating personalized diagnostic and prognostic responses that are both efficient and effective.